$BRKR

Bruker Corporation's stock rose 6.3% to $59.45 on Wednesday, part of a broader sector-wide rally. Peers TXG, 1521.HK, ADPT, and AVTR also saw gains of 3.7% to 13.3%. The move was driven by sector rotation and institutional interest, with no company-specific news. Bruker's trading volume reached 597,428 shares, adding value to its $9.1 billion market cap.

JPMorgan downgraded Bruker to 'Neutral' from 'Overweight' and set a price target of $60. The company's stock has seen a 5-day change of 56.19 USD, a 1st Jan change of -0.11%, and a 19.27% increase over a longer period.

Bruker (BRKR) announced new mass spectrometry workflows and a $6M NMR order from UC Berkeley. Analysts expect 5.0% annual revenue growth and margin expansion to 13.4% by 2029, with earnings turning positive. However, execution risks and debt concerns remain. Current P/E is distorted by losses, trading lower than the life sciences peer group.

Analysts updated recommendations: Flutter (FLUT.L) downgraded to neutral with target cut to $119; Constellation Brands (STZ) kept underperform with target lowered to $110; eBay (EBAY) maintained underperform with target reduced to $75; Meta (META) kept overweight with target raised to $796. Other companies also received updates.

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.

Bruker Corporation (BRKR) reported Q3 earnings that exceeded expectations, with non-GAAP EPS of $0.45. Shares rose nearly 7% despite cautious guidance. The company faces underlying headwinds but is in transition, according to the report.

Bruker (BRKR) shares fell 6.3% after UBS initiated coverage with a Neutral rating and a $65 price target, citing AI-related tailwinds and ongoing headwinds. The company's stock has been volatile, with a 17.7% drop last month due to missed revenue expectations and lowered guidance. BRKR is up 13.1% YTD but trades 15.5% below its 52-week high.

Bruker (BRKR) announced a supply collaboration with Luvata to scale up production of RRP superconductors for fusion energy. BEST unit revenue grew 11.9% YoY to $74.2M in Q2, with non-GAAP EPS at $0.49. GAAP results showed a $65.3M loss due to goodwill impairments. Bruker maintains full-year non-GAAP EPS growth target of 15-17%.

Bruker Corporation's BEST segment and Luvata Materials Solutions announced a collaboration to supply high-performance RRP superconductors for magnetic confinement fusion projects. The partnership aims to increase manufacturing capacity and supply chain resilience. Bruker (Nasdaq: BRKR) and Luvata will support global fusion energy initiatives, leveraging their expertise in superconducting technologies. The collaboration is driven by growing demand for fusion energy solutions.

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.